Label-free detection for glycosylation profiling


04-05-2011

TTP LabTech introduce a balanced approach to protein-protein interaction.

Royston, UK (3rd May 2011) – At the Seventh annual PEGS conference to be held in Boston, MA, TTP LabTech will release data demonstrating the use of their novel acoustic biosensor, LIBRA2, for the study of glycosylation patterns on cell membranes. TTP LabTech is inviting scientists to Booth 304 to view the data and discuss future developments and applications of the LIBRA2 technology.

Changes in glycan structures are becoming increasingly recognized as one of the most prominent biochemical alterations associated with malignant transformation and tumourogenesis. Exploiting Resonant Acoustic Profiling (RAP), LIBRA2 has been used to characterise the binding of label-free lectin onto immobilised mammalian cells creating a profile of glycolipoprotein and glycolipid expression. Such studies are often found to be challenging by traditional analytical techniques.

Biosensor Product Manager, Dr Helge Schnerr is excited about the potential of LIBRA2 to profile the glycosylation patterns of cancer cells and commented that “the ability to define both the nature of such glycans, using lectins or monoclonal antibodies with this novel cell-based acoustic biosensor, may provide useful diagnostic or prognostic information in oncology research and therapy”.

Mirrorball®, the high sensitivity laser scanning microplate cytometer for antibody discovery, will also be available for demonstration with TTP LabTech at Booth 304. For more information on the applications and capability of the LIBRA2® or Mirrorball® systems, please visit TTP LabTech at the Seventh annual PEGS conference, or visit www.ttplabtech.com/products/libra2/index.html or www.ttplabtech.com/mirrorball.

About TTP LabTech Ltd
Based near Cambridge, UK, TTP LabTech supplies laboratory instrumentation for the healthcare, biotech and pharmaceutical sectors. TTP LabTech’s products are designed to increase efficiency, effectiveness, flexibility or overall capability in key biopharmaceutical research processes including compound storage (comPOUND®), low volume liquid handling (mosquito®), high content screening (Acumen®), antibody discovery (Mirrorball®) and sample analysis management (LAB2LAB).
www.ttplabtech.com  
 

To read more information, click here.

TTP is an independent technology company where scientists and engineers collaborate to invent, design and develop new products and technologies. Working across a wide spectrum of industries including health, telecoms, industrials and consumer, TTP creates breakthrough solutions that bring strong commercial value to clients and the benefits of technology to all.

TTP plc